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Abstract: Arterial stiffness has been accumulating evidence as an intermediate cardiovascular  
endpoint. It has been established as an independent risk marker for cardiovascular disease, and  
reflects the dissociation between chronologic and biologic age of large arteries-attributing earlier 
the risk that a normal vascular ageing process had installed to occur several years later. The  
concept of Early Vascular Ageing (EVA) is developed to establish primordial prevention, identify-
ing individuals whose ageing path has been accelerated either by inherent features, interaction  
with the environment or arterial exposure to several types of insults that evolve to medial layer 
morphological changes. Understanding the pathophysiology of vascular ageing, its consequences 
and therapeutic opportunities is therefore an advantage that could be translated in time of prevention 
and survival free of cardiovascular disease. As the EVA construct is advancing, new features appear 
as interesting to better translate it into clinical practice. 
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1. INTRODUCTION 
 Early Vascular Ageing (EVA) is an evolving concept [1-
3] that has been growing around the accumulating evidence 
surrounding arterial stiffness as an intermediate end-point 
and an independent predictor of cardiovascular disease and 
cardiovascular as well as total mortality [4]. This construct 
(EVA) is elaborating on the core idea that it is possible to 
identify at an early stage subjects with signs of an unsuccess-
ful vascular ageing. This unsuccessful ageing (accelerated 
ageing), if undetected otherwise, would lead those subjects 
into earlier development of cardiovascular disease (CVD) 
and irrecoverable residual risk in spite of therapeutic primary 
or secondary prevention measures undertaken, later in time. 
 The purpose of this overview is to: 1) briefly review key 
pathophysiologic concepts concerning vascular ageing and 
associated risk of development of cardiovascular disease, as  
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well as the established value of pulse wave velocity (PWV), 
a direct measurement of arterial stiffness, as a valuable bio-
marker of cardiovascular risk; 2) discuss existing definitions 
of EVA and its premises; 3) propose the clinical applicability 
of the concept to specific target groups; 4) review existing 
records of the prevalence of EVA in order to gauge future 
directions concerning therapeutic intervention and research; 
and to finally 5) debate therapeutic implications for subjects 
with EVA. 
2. CHANGES IN THE ARTERIAL TREE IN HYPER- 
TENSION CONDITIONING PROGRESSION TO 
ARTERIAL STIFFNESS AND ITS COMPLICATIONS 
 The process of arterial ageing begins during the human 
intra-uterine life. During this period, not only the uterine 
environment, but also the development of the fetus and its 
cardiovascular system are under the influence of maternal 
hormonal, socio-economical and health characteristics [5, 6]. 
The extent of the success of ageing could intuitively be 
measured as the accumulated number of chronologic years 
that a subject survives without disease or disease induced 
limitations. Still, one must be aware that the process of nor-
mal vascular ageing can be accelerated by a combination of 
the exposure to different factors that insult the arterial wall 
and the time of exposure to these insulting factors [7]. Thus, 
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biologically speaking, the arterial wall can in fact appear 
older than its chronological age, reflecting adaptive changes 
to repeated insults and exposing earlier the subjects to the 
risk of development of cardiovascular disease that they 
would be subjected only years later [8].  
 With advancing age, and especially after 30 years of life, 
large arteries progressively lose their elastic properties [9, 
10]. The process of arterial stiffening is mainly due to 
changes in the medial layer of the arterial wall, altogether 
referred to as arteriosclerosis. The normal media is com-
posed of elastin, collagen, vascular smooth muscle cells 
(VSMC) and a mucopolysaccharide matrix [11]. These  
components are distributed in different proportions as we 
move from central (elastic) to peripheral (muscular) arteries; 
with age, large arteries are characterized by: 1) a reduction of 
the elastin component and changes in the interaction of 
elastin lamellae; 2) an increase in collagen and mucopoly-
saccharide matrix; 3) a reduction of VSMC and an increase 
in VSMC stiffness; and 4) a decreased activity in proteolytic 
enzymes, reducing the vessel’s remodeling process as in-
tended [11, 12]. 
 Changes in the medial layer occur normally with ageing, 
and are the result of an equilibrium established between  
3 key mechanisms: 1) cyclic stress (reflecting the cardiac 
cycle and subsequent repeated changes in the arterial struc-
ture promoted by the incident and the retrograde flow and 
pressure waves); 2) the arterial wall’s repair mechanisms that 
correct the injuries promoted by this mechanical/elastic 
stress (9), but also, the insults to the arterial wall provoked 
by different aggressors (excessive blood pressure, dyslipi-
demia, diabetes and its advanced glycation end (AGE) prod-
ucts, smoking, inflammation, oxidative-stress, endothelial 
dysfunction and so many others) [13-18]; at the extreme of 
the possibilities leading to stiffer arteries, are the acquired or 
inherited lack of effective repairing mechanisms of the arte-
rial wall or hereditary conditions promoting vascular ageing 
[6, 19]. All these conditions can lead to an acceleration of 
medial changes naturally observed with age, and hence, in-
creased cardiovascular risk. 
 As the central arteries become stiffer, they maintain their 
conduit function, but progressively lose their buffering prop-
erty, transmitting high energy pulsatility into the vascular 
bed of organs highly vascularized but prepared only to deal 
with a continuous flow of blood, like the brain and the kid-
ney – promoting target organ damage through pulsatility 
energy transmission, especially when the proximal/distal 
large arteries mismatch is lost, in response to the premature 
ageing, thus stiffening, of large arteries [9, 11, 20-23]. 
 Finally, and concurring to the pathophysiology of cardio-
vascular disease promoted by changes in the arterial wall, 
stiffer arteries transmit not only the forward, but also the 
reflected pressure waves with higher velocity, and eventually 
with greater magnitude [24]. This earlier reflection will su-
perimpose on the cardiac after-load and increase central and 
peripheral blood pressures, increasing the pulsatile energy 
transmitted to target organ damage and reducing coronary 
perfusion (as the coronary flow should be assured by the 
reflecting wave later in the diastole) [12, 24]. 
2.1. The Blood Pressure Paradox in its Relationship with 
Arterial Stiffness 
 The main determinants of pulse wave velocity (PWV) are 
age and blood pressure [25-27]. In a paradoxical sense, and 
as demonstrated by preceding arguments, increasing arterial 
stiffness will promote augmented pulse wave reflection and 
concurrent blood pressure increase. Until recently, this 
would appear a cyclic event, with higher blood pressure in-
creasing arterial stiffness, and the later promoting higher 
levels of blood pressure. New evidence has surfaced in lon-
gitudinal studies, showing that not only is arterial stiffness a 
predictor of future development of hypertension [28, 29],  
but also that PWV and peripheral blood pressure have  
divergent evolutions in time [27, 30] and according to  
gender, obviating a partial independence of these players, 
who must have other variables explaining their variance. 
This is an argument in favor of directly measuring arterial 
stiffness, instead of estimating it through blood pressure and 
age algorithms. 
 On one hand, one can find a link between arterial  
stiffness and other blood pressure characteristics that have an 
impact in cardiovascular mortality: blood pressure variabil-
ity, heart rate variability and impaired baroreceptor function 
(causing orthostatic hypotension) [31]; on the other hand, 
several mechanisms have been associated to the accelerated 
development of arterial stiffness and (indirectly) of increased 
blood pressure: the metabolic syndrome, inflammation and 
neurohormonal disorders, all inducing endothelial dysfunc-
tion [32]. 
3. Arterial Stiffness and its Evolution as an Independent 
Predictor of Cardiovascular Risk 
 The degree of arterial stiffness provoked by arteriosclero-
sis generates a faster pressure wave through a more rigid 
conduit. Thus, the degree of stiffness (or disease of the me-
dia, or arteriosclerosis) can be measured using pulse wave 
velocity, considered as the gold standard measure [33]. PWV 
has been accumulating evidence as an intermediate cardio-
vascular risk marker, after initial observations by Avolio et 
al. in China [34, 35]. 
 Its independent power to predict cardiovascular disease 
was first determined in high-risk groups (chronic kidney 
disease, hypertension, diabetes) [36-39] and finally in  
the general population or in apparently healthy individuals 
[40-42]. 
 For each increase in PWV of 1m/s the risk of cardiovas-
cular events or all-cause mortality increases by 14 to 15% 
[43]; or if one prefers, by each increase in 1 standard devia-
tion (SD) of PWV, the risk of cardiovascular events in-
creased by 30% [4] – this most recent meta-analysis had yet 
another particular detail: it associated PWV with an in-
creased risk of stroke, especially in younger age classes. 
 In a recent consensus document endorsed by the Euro-
pean Society of Cardiology and the Artery Society [44], ca-
rotid-femoral PWV has been established as a biomarker that 
is highly sensitive for identification of subjects with different 
phenotypes and with clinical relevance for therapy guidance,  
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as well as bearing risk prediction improvement; nowadays it 
fulfills 8 of the 9 criteria established by the two societies to 
be considered a valuable biomarker (by use of an upgraded 
classification from Hlatky and colleagues [45]), and it gathers 
a “IIa” recommendation (with an “A” level of evidence) for 
use in risk stratification [44] – one of the three new biomark-
ers that achieve this classification. It is important to remem-
ber that the 2013 ESH-ESC Guidelines for the management 
of arterial hypertension, graded this recommendation as “IIa” 
(PWV should be considered to detect arterial stiffening) with 
a “B” level of evidence [46]. 
 The definition of reference values for pulse wave veloc-
ity, according to age groups (in the “healthy population”) 
and according to age and blood pressure class (in the  
“reference population” – corresponding to subjects that  
either smoke, have high-normal blood pressure or untreated 
hypertension or dyslipidemia) [25], has established a  
grid against which one can now compare the dimension of 
arterial damage expected for a given age in predetermined 
circumstances, identifying subjects that are off the grid as 
evidencing an abnormal vascular ageing process. 
4. THE CONCEPT AND PROPOSED DEFINITIONS 
OF EARLY VASCULAR AGEING 
 The EVA concept is a tool for early identification of sub-
jects that could benefit the most from early primary preven-
tion measures. It embraces the knowledge of all the 
physiopathology of arterial ageing described summarily in 
previous sections of this overview, as well as all the singular 
capability of risk prediction concerning CVD by PWV 
measurements (as a proxy of arterial stiffness or arterioscle-
rosis) to answer the following questions: do the large arteries 
of an individual exhibit signs of accelerated or unsuccessful 
ageing? Does this abnormal rate of arterial ageing place this 
individual at a risk level for cardiovascular event that would 
imply early clinical intervention? 
4.1. Current Methods Used to Identify EVA Subjects 
 The palpable definition of a subject exhibiting EVA is a 
work in development. For the time being it has relied mainly 
on three different methods: 1) to use the normal distribution 
of PWV values in a population, and define as EVA subjects 
those who place themselves 2 standard deviations above the 
mean PWV value [47]; 2) to transform all PWV values of 
the population into z-scores and classify as EVA those sub-
jects who present z-score above the 95th percentile [47]; or 3) 
the last method is similar in concept to the previous two pre-
sented, but it uses as reference for normality those values 
published in the European Reference Values Collaboration 
[25]: EVA subjects are those who have a PWV value 2 SD 
above the “normal” PWV expected for age (according to the 
European Reference Values Collaboration) or whose z-score 
is above the 97.5th percentile (using the age attributed “nor-
mal” PWV value as comparator) [48]. 
 These are still probably incomplete and rough methods to 
establish those who have EVA. Will subjects having PWV 
within the 90th percentile of the distribution be free of con-
cern regarding their future cardiovascular health? Are there 
any other biomarkers that can be added to these definitions 
or that can complement them? For this matter, much data has 
been published concerning carotid Intima Media Thickness 
(cIMT), and it makes sense that we add a direct observation 
of the arterial wall to also identify those whose medial di-
mension has enlarged. Several studies and meta-analysis 
have supported this premise, evidencing that cIMT increases 
cardiovascular risk prediction beyond established risk algo-
rithms, as well as it presents a modest risk reclassification 
power [49-51]; in one other meta-analysis however, the 
added value of measuring cIMT above the Framingham risk 
score was minor and precluded its clinical use [52]. However, 
the inclusion of this biomarker in the identification of EVA 
subjects has already spurred interest in the scientific com-
munity [53], and the fact that recent European reference val-
ues of cIMT, obtained with high resolution echo-tracking, 
have been published is obviously a facilitator of its transition 
to clinical use [54]. Results from the CARDIA, the Amster-
dam Growth and Health Longitudinal and the Bogalusa stud-
ies are seriously encouraging in this domain as they evidence 
a correlation of early exposure to cardiovascular risk factors 
and concurrent changes in cIMT [55, 56], as well as devel-
opment of cognitive dysfunction [57]. 
 Should EVA subjects be considered as such if one of the 
characteristics (PWV or cIMT) present higher than expected 
(above the 97.5th percentile) values for healthy individuals of 
the same age group, using the European Reference Values 
Collaboration as comparators? Or should they present both 
characteristics simultaneously? These are questions to be 
answered in the future. 
5. WHO, HOW AND WHEN TO SCREEN? THE EVA-
HAS CONSTELLATION 
5.1. Who 
 Even if the measurement devices of PWV are easy to use, 
their availability is not yet disseminated in clinical practice. 
The European Society of Hypertension / European Society of 
Cardiology guidelines already include PWV as a part of tar-
get organ damage evaluation recommended for all hyperten-
sive subjects [46], which constitutes a clear opportunity to 
evaluate EVA, whether target organ damage is absent (i.e., if 
PWV < 10 m/sec), or not. Still, many other individuals with 
cardiovascular risk factors, or chronic inflammatory diseases 
should be screened for EVA [16]; as such, individuals with a 
positive familial history of premature cardiovascular disease, 
obstructive sleep apnea, chronic obstructive pulmonary dis-
ease, chronic inflammatory rheumatologic and immunologic 
conditions [58, 59], diabetes mellitus, dyslipidemia (espe-
cially familial hereditary forms), smoking, or chronic kidney 
disease, amongst others, should have their arterial stiffness 
evaluated. 
5.2. The EVA-HAS Constellation 
 Attention has also been devoted to hemodynamic signs 
that appear as a consequence of arterial stiffness, and that 
could be incorporated in what one could denominate as an 
early vascular ageing – hemodynamic ageing syndrome 
(EVA – HAS) [31]; postural hypotension, elevated blood 
pressure variability [60], and isolated systolic hypertension 
could, thus, be also signals that when detected could lead the 
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clinician to evaluate arterial stiffness and evidence of EVA. 
It can be suggested that morphological changes in the arterial 
wall constitute the fundament for EVA, but that the hemody-
namic changes that occur as a consequence of the morpho-
logical changes can be regarded as HAS. 
5.3. When 
 Scheduling an arterial stiffness evaluation should be 
prompt during the first evaluation of every hypertensive in-
dividual, or during the first evaluation of any of the indi-
viduals showing the above mentioned conditions or signs. A 
special attention should still be addressed to subjects that, 
during their first clinical evaluation, are classified by risk 
algorithms as having moderate added risk, as these are the 
ones most benefiting from reclassification into higher risk 
classes and concurrent treatment intensification [61]. 
5.4. How 
 The conditions of correct measurement of PWV have 
been extensively reviewed in several documents [33] and 
recently in a consensus document [62]. Three sets of recom-
mendations are particularly noteworthy: 1) the pre-
measurement conditions to observe – fasting (including no 
caffeinated beverages), no smoking, a 10 minute rest before 
examination in a quiet room and in the supine position; 2) 
the direct carotid – femoral distance should be measured in a 
straight line, and the obtained PWV with this distance should 
be multiplied by 0.8 to obtain the final PWV value; 3) at 
least two measurements that do not differ more than 0.5 m/s 
should be taken for each individual. Conditions precluding 
the inability to use the technique should be taken into con-
sideration [62]. Another aspect to consider pertains to the 
standardization of PWV obtained with different devices and 
using different peripheral blood pressure measurements to 
calibrate the pulse wave form (systolic blood pressure + dia-
stolic blood pressure vs. mean blood pressure). This issue 
has been fully addressed elsewhere [25]. 
6. PREVALENCE OF EARLY VASCULAR AGEING 
IN THE GENERAL POPULATION 
 Till recently, no estimate of the prevalence of EVA had 
been published. In a cohort study, including a randomly se-
lected representative sample of two adjacent cities in the 
north of Portugal (Guimarães and Vizela), a thorough pheno-
typic evaluation of subjects concerning cardiovascular risk 
was performed. In a two-visit screening study, collection of 
data regarding clinical history, extensive biochemical 
workup of blood and urine, measurement of central hemody-
namic parameters and cognitive function was performed in 
three thousand and thirty eight subjects. A full description  
of the followed methodology has been reported elsewhere 
[63]. 
 Of the 2542 subjects who completed the observation 
plan, we registered a mean age of 45.5 years and a 55% 
prevalence of females. After transforming PWV values into 
z-scores we compared the PWV values of our subjects with 
what would be the expected PWV value for someone his/her 
age in the normal (“healthy”) population of the European 
Reference Values Collaboration. Using this method we ob-
served that 12.5% of the population showed signs of EVA. 
The prevalence of EVA was mainly occurring in the age 
classes below 50 years, and the most striking observation 
was that 26.1% of individuals under 30 years of age pre-
sented its features, according to this definition, with a sig-
nificantly increased prevalence in young males [48]. As we 
previously discussed, a cut-off value is always arbitrary and 
the fact is that cardiovascular risk has an increasing continu-
ous relationship with the increase of PWV values. Thus, also 
worrisome was the finding, in this same study, that approxi-
mately 35% of individuals aged less than 40 years present a 
PWV value that is above the 90th percentile of PWV ex-
pected for his/her age according to the European Reference 
Values Collaboration [25]. These data are of importance 
when we consider that the two studied adjacent cities are 
located in the region of Western Europe with the highest 
stroke rate incidence [64, 65]. 
 Shortcomings of this observational study should be ac-
knowledged, mainly due to the fact that only one PWV 
measurement was performed in each subject, and that a his-
torical bias can have been introduced in the interpretation of 
results, as some of the studied cohorts that are included in 
the European Reference Values Collaboration have been 
examined 20 years ago [48]. 
 Even if, so far, no other study has determined the preva-
lence of EVA, it is noteworthy to analyze two different as-
pects that could offer partial explanation for these results: a) 
following a political revolution approximately 40 years ago, 
Portugal has experienced a significant change in both living / 
nutritional habits and social behavior; the truth to the matter 
is that nowadays, statistics show high levels of childhood 
and teenager overweight and obesity as well as physical in-
activity and elevated blood pressure levels [66, 67] – for 
subjects below 40 years of age, for instance, blood pressure 
levels are significantly above the minimum theoretical expo-
sure risk values for the development of cardiovascular dis-
ease [68]; b) in several studies looking into another vascular 
biomarker (cIMT), an inverse relationship has been found 
between the maintenance of ideal cardiovascular health be-
haviors in childhood and measured values of cIMT [69-71]. 
 On a totally different (but related) topic, one must con-
sider the use of EVA in different fields of clinical cardiovas-
cular disease prevention. For example, in a case– control 
study involving 223 catheter laboratory workers, a signifi-
cant association was found between high risk exposure to 
radiation, increased cIMT and shorter telomere length [72]. 
Thus, radiation exposure is another factor that could to be 
involved in accelerated biological ageing. This opens new 
population targets to evaluate for EVA, i.e. occupationally, 
circumstantially or warfare exposed to radiation. 
7. THERAPEUTIC IMPLICATIONS: DE-STIFFENING 
THE ARTERIAL WALL 
 The role of arterial stiffness as a surrogate marker for 
cardiovascular disease, with significant implications for the 
risk of its development has been well established and dem-
onstrated both herein and in the extensive research work 
presented by different research teams around the world. The 
issue of treatment of arterial stiffness as a therapeutic target 
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is still subject to debate, with clear ramifications to the ra-
tional of clinical approach of the patient with EVA. 
 The pharmacologic treatment options for subjects with 
EVA, according to the existing evidence, are mainly depend-
ent of the fact that the same individual has hypertension or 
not. In fact, using anti-hypertensive drug therapy will, in 
parallel, reduce arterial stiffness by decreasing the stiffness 
proportion corresponding to the pressure load of collagen 
fibers in the arterial wall, by increased blood pressure. With 
current existing evidence, (and due to the lack of trials show-
ing that PWV can itself be a therapeutic target with proven 
cardiovascular benefit) these drugs can only be used in hy-
pertensive subjects. 
 Still, no mistake should be made that, in the EVA sub-
jects with no clinical indication to use anti-hypertensive 
treatment, other ways of reducing blood pressure (and thus 
obtain stiffness reduction through the above mentioned 
mechanism) should be recommended in so far as this blood 
pressure reduction would not harm the individual, taking into 
account his/her particular clinical features (Tables 1 & 2); 
these non-pharmacological blood pressure reductions should 
be achieved through reduction of salt consumption [73], ap-
propriate regular physical activity, weight loss and reduction 
of alcohol consumption [74, 75]. 
 Other therapeutic interventions for the subject with EVA 
include pragmatic and strict attitudes on: a) smoking cessa-
tion; b) detection and control of traditional and non-
traditional cardiovascular risk factors (diabetes, dyslipide-
mia, abdominal obesity); c) detection and reversion of the 
metabolic syndrome [17]; d) appropriate primary prevention 
measures and treatment targets, in accordance with the 
global cardiovascular risk class [74]; and e) control of in-
flammatory disease states, reduction of oxidative stress and 
improvement of endothelial dysfunction. One capital issue in 
these subjects is close follow-up and constant reassessment 
of interventions. 
7.1. Arterial Stiffness and EVA in Hypertensive Patients 
 For the EVA subject with hypertension, other pharma-
cologic therapeutic options can be included in the treatment 
strategy of the patient, in accordance with the existing evi-
dence. Two particular aspects should be considered: 1) all 
the above mentioned treatment strategies, which are appro-
priate for the non-hypertensive EVA subject, are still indi-
cated in the EVA hypertensive patient; 2) The fundamental 
cornerstone of treatment is blood pressure control – even if 
one must not put aside the role in arterial remodeling (and 
arterial stiffness reduction) achieved by a long term use of 
Table 1. Therapeutic interventions in subjects with Early Vascular Aging. 
Obtain non-pharmacologic and clinically sustainable reductions of BP by reducing salt consumption, appropriate regular physical  
activity, weight loss and reduction of alcohol consumption 
Smoking cessation 
Control of traditional and non-traditional cardiovascular risk factors (hyperglycemia/diabetes, dyslipidemia, abdominal obesity) 




Control of chronic inflammatory disease states 
Institute equally all the non-pharmacologic / healthy lifesytle measures proposed for non-hypertensive subjects 
Control Blood Pressure (independently of drug class used) Hypertensive 
Subjects  
If possible, use preferentially ACE inhibitors, ARB’s, aldosterone antagonists, calcium channel blockers and/or vasodilating beta-
blockers. Inhibitors of the renin – angiotensin system and calcium channel blockers (either alone or in combination, should be preferred) 
 
Table 2. Summary about EVA.  
1. EVA is an evolving concept aiming at earlier identification of subjects at increased risk of CVD 
2. The BP/Arterial Stiffness paradox: BP is a main determinant of Arterial stiffness; still evidence shows that these variables have a divergent 
evolution with age, according to gender, making it clear that they bear different prognostic information in terms of CVD risk 
3. Arterial Stiffness is an independent predictor of CVD, both in high-risk CV subjects and at the general population level 
4. Screening for EVA should be done in; hypertensive patients (with no TOD); individuals with CVRF or chronic inflammatory diseases; subjects 
with moderate risk for the development of CVD 
5. In one population based study, the prevalence of EVA was 12.5%; one out of every for subjects bellow  
30 years of age presented with this characteristic 
6. Therapeutic implications – there are two distinct sets of recommendations for therapeutic attitudes in subjects with EVA,  
considering their hypertension status (please see Table 1) 
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antihypertensive drugs, beyond blood pressure reduction 
[76]. 
 Having said this, particular drugs may have beneficial 
effect on arterial stiffness reversion, other than blood pres-
sure control. A particular attention should be paid to subjects 
with already low diastolic blood pressure but high pulse 
pressure levels, in whom aggressive decrease of blood pres-
sure could compromise diastolic perfusion – nitrates and 
nitric oxide donors, acting more selectively in large arteries 
are options to consider and closely study for this purpose 
[77]. In a seminal work, Guérin and colleagues followed 150 
individuals with end-stage renal disease for approximately 
52 months, and showed that those who responded to anti-
hypertensive treatment with blood pressure lowering and 
pulse wave velocity reduction were the ones with the better 
survival prognosis, as opposed to those who, having re-
sponded to blood pressure reduction, did not register similar 
PWV reduction [78]. 
 Much information has been published regarding blockers 
of the renin-angiotensin-aldosterone system (RAAS) as cor-
nerstone drugs to use whenever arterial stiffness reversibility 
is a consideration during treatment, independently of BP 
reduction [79-82]. 
 A sub-study of the PEACE trial [83], compared the long 
term use of trandolapril vs. placebo in 300 subjects with sta-
ble coronary heart disease and left ventricular ejection frac-
tion >40%, to observe that those subjects under trandrolapril 
treatment had lower PWV values at the end of the study, 
even after adjustment for the decrease in mean arterial pres-
sure (also higher in the trandolapril arm). The authors con-
cluded that an effect of PWV reduction could be associated 
to the use of ACE inhibition, beyond blood pressure lower-
ing [83]. 
 A post-hoc analysis of the EXPLOR trial [84], a prospec-
tive, randomized, parallel groups multicenter trial with a 
PROBE design, where 393 subjects with essential hyperten-
sion were randomized to treatment with valsartan (plus am-
lodipine at week 8) or atenolol (plus amlodipine at week 8) , 
has shown that at week 24, 47% of the reduction in PWV 
(after adjustment for blood pressure and heart rate) in the 
valsartan arm was independent of changes in mean blood 
pressure. In a different prospective, randomized, open-label, 
blinded end point (PROBE) study, 207 hypertensive patients 
were treated with olmesartan for 24 weeks (with either azel-
nidipine or hydrochlorothiazide added on at week 12), with 
the olmesartan/azelnidipine arm showing significant superi-
ority in decreasing PWV, beyond achieved blood pressure 
reduction [85]. 
 A meta-analysis of individual data performed by Ong et 
al., showed that, in 294 previously untreated mild to moder-
ate hypertensives, arterial stiffness could be improved by 
anti-hypertensive treatment beyond blood pressure reduction, 
particularly pointing out the efficacy of angiotensin convert-
ing enzyme inhibitors (ACEi), angiotensin receptor blockers 
(ARB), calcium channel antagonists (CCA) and beta-receptor 
blockers (ß-block) – the later in long term trials. More im-
portant in this meta-analysis was the observation of a disso-
ciation of PWV and blood pressure evolution and response 
to treatment with time, following blood pressure control 
[86]. The data on ACEI ability to reverse arterial stiffness 
has been partially reinforced by another meta-analyzes and 
meta-regression of randomized control trials, including 23 
studies; yet, ACEI showed no clear superiority over other 
drugs antihypertensive drugs in reversing PWV, but a sig-
nificant benefit in reducing augmentation index (Aix) [87, 88]. 
8. CONCLUSION AND FUTURE DIRECTIONS 
 Even if much evidence has been accumulated concerning 
the important independent prognostic value of c-f PWV for 
the development of CVD, so far no single published study 
has been structured to show evidence that a treatment strat-
egy aimed at reducing arterial stiffness could be beneficial in 
terms of cardiovascular disease prevention and cardiovascu-
lar risk reduction. New study strategies have already been 
devised for this purpose, and the ongoing SPARTE trial [89] 
should bring new insights to this issue. 
 The EVA concept will evolve, and new definitions in-
cluding other biomarkers (e.g. cIMT) could facilitate its 
translation to clinical use as a concept embedded in primor-
dial prevention of cardiovascular disease. 
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